ACUVUE THERAVISION WITH KETOTIFEN Drug Patent Profile
✉ Email this page to a colleague
When do Acuvue Theravision With Ketotifen patents expire, and when can generic versions of Acuvue Theravision With Ketotifen launch?
Acuvue Theravision With Ketotifen is a drug marketed by Johnson Johnson Visn and is included in one NDA. There are two patents protecting this drug.
This drug has forty-four patent family members in fifteen countries.
The generic ingredient in ACUVUE THERAVISION WITH KETOTIFEN is ketotifen fumarate. There are five drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the ketotifen fumarate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Acuvue Theravision With Ketotifen
A generic version of ACUVUE THERAVISION WITH KETOTIFEN was approved as ketotifen fumarate by APOTEX INC on May 9th, 2006.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ACUVUE THERAVISION WITH KETOTIFEN?
- What are the global sales for ACUVUE THERAVISION WITH KETOTIFEN?
- What is Average Wholesale Price for ACUVUE THERAVISION WITH KETOTIFEN?
Summary for ACUVUE THERAVISION WITH KETOTIFEN
| International Patents: | 44 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| What excipients (inactive ingredients) are in ACUVUE THERAVISION WITH KETOTIFEN? | ACUVUE THERAVISION WITH KETOTIFEN excipients list |
| DailyMed Link: | ACUVUE THERAVISION WITH KETOTIFEN at DailyMed |
US Patents and Regulatory Information for ACUVUE THERAVISION WITH KETOTIFEN
ACUVUE THERAVISION WITH KETOTIFEN is protected by two US patents and one FDA Regulatory Exclusivity.
Patents protecting ACUVUE THERAVISION WITH KETOTIFEN
Methods for stabilizing oxidatively unstable compositions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Methods and ophthalmic devices used in the treatment of ocular allergies
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
FDA Regulatory Exclusivity protecting ACUVUE THERAVISION WITH KETOTIFEN
NEW PRODUCT
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Johnson Johnson Visn | ACUVUE THERAVISION WITH KETOTIFEN | ketotifen fumarate | DRUG-ELUTING CONTACT LENS;OPHTHALMIC | 022388-001 | Feb 25, 2022 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Johnson Johnson Visn | ACUVUE THERAVISION WITH KETOTIFEN | ketotifen fumarate | DRUG-ELUTING CONTACT LENS;OPHTHALMIC | 022388-001 | Feb 25, 2022 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Johnson Johnson Visn | ACUVUE THERAVISION WITH KETOTIFEN | ketotifen fumarate | DRUG-ELUTING CONTACT LENS;OPHTHALMIC | 022388-001 | Feb 25, 2022 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ACUVUE THERAVISION WITH KETOTIFEN
See the table below for patents covering ACUVUE THERAVISION WITH KETOTIFEN around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| European Patent Office | 2010143 | PROCÉDÉS DE STABILISATION DE COMPOSITIONS INSTABLES DE MANIÈRE OXYDATIVE (STABILIZED OPHTHALMIC COMPOSITIONS COMPRISING OXIDATIVELY UNSTABLE COMPONENTS) | ⤷ Sign Up |
| Spain | 2623532 | ⤷ Sign Up | |
| Spain | 2624960 | ⤷ Sign Up | |
| Australia | 2007305205 | Methods and ophthalmic devices used in the treatment of ocular allergies | ⤷ Sign Up |
| Argentina | 059928 | METODOS Y DISPOSITIVOS OFTALMICOS USADOS EN EL TRATAMIENTO DE ALERGIAS OCULARES | ⤷ Sign Up |
| South Korea | 101454674 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
